PROBY screening uncovers target-selective fluorescent probes for tau, BCL-2 and TDP-43
The PROBY deep-learning pipeline screened 26,416 target-validated molecules for useful optical properties, identified 11 candidates for testing and found target-responsive probes PE859 (tau), obatoclax (BCL-2) and B3 (TDP-43). The study reports selectivity assays, cell/tissue labeling and ex-vivo tumor imaging with obatoclax. AI-guided structural modification of PE859 yielded 859-2, which enabled in-vivo two-photon and cleared-brain imaging of tau pathology in P301S transgenic mice; its measured tau-aggregate dissociation constant was 54.8 nM.
Technology: PROBY two-stage message-passing neural network pipeline (PROBY-L1 fluorescence classification and PROBY-L2 photophysical-property prediction)
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The PROBY deep-learning pipeline screened 26,416 target-validated molecules for useful optical properties, identified 11 candidates for testing and found target-responsive probes PE859 (tau), obatoclax (BCL-2) and B3 (TDP-43).
- Still unknown: The PROBY hits are repurposed molecules from a target-validated library, not newly synthesized compounds. Target/probe performance is assay-specific; tau in-vivo imaging was demonstrated in a small transgenic-mouse study (n=3), not humans. This entry describes probe function and imaging results, not treatment effects or diagnostic performance in patients.
- AI role: PROBY ranked target-validated compounds by predicted fluorescence and seven optical properties, enabling selection and experimental verification of target-specific probes; the team then used AI-predicted structural modification alongside synthesis and bioassays to optimize PE859 into 859-1/859-2.
Evidence sources: https://pubmed.ncbi.nlm.nih.gov/41441857/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review scope and date are not recorded; source checked does not establish full-text review.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.